{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:05Z","timestamp":1747181105454,"version":"3.40.5"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,25]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">RET<\/jats:italic>-rearranged fusions have been considered as oncogenic drivers in 1% to 2% of non-small cell lung cancers (NSCLC). ARROW study has demonstrated a new selective RET tyrosine kinase inhibitors (TKIs) shows remarkable and durable responses in <jats:italic toggle=\"yes\">RET<\/jats:italic>-rearranged NCSLC. In this study mainly recruited patients with common fusion partners <jats:italic toggle=\"yes\">KIF5B<\/jats:italic> and <jats:italic toggle=\"yes\">CCDC6<\/jats:italic>. There is still a lack of definitive conclusions about effective of rare RET fusion variants to anti-RET therapies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case report:<\/jats:title>\n            <jats:p>A Chinese 58-year-old female renal insufficient patient with no history of smoking was diagnosed as stage IIIA (T2N2M0) lung adenocarcinoma. Next-generation sequencing targeting 520 cancer-related genes was performed on the pleural effusion samples and revealed 2 novel RET fusions LINCO1264-RET and SEMA5A-RET, concomitant with a common CCDC6-RET.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Management and outcome:<\/jats:title>\n            <jats:p>The patient was first treated with multiple lines of chemotherapy and switched to lenvatinib but failed to respond. Due to renal insufficiency, she subsequently received pralsetinib with gradually reduced dosages (400 mg-300 mg-200 mg-100\u2009mg qd) and achieved a partial response (PR) lasting for more than 10 months, accompanied by the declined allele frequencies of all 3 RET fusions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion\/conclusions:<\/jats:title>\n            <jats:p>We reported the first case of the pralsetinib efficacy in NSCLC with 3 concurrent RET fusions. Our case also indicates the sensitivity of the newly identified RET fusions to this RET selective inhibitor pralsetinib, and highlights the low-dose treatment option for patients with renal insufficient background.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000031480","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T20:08:43Z","timestamp":1669838923000},"page":"e31480","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report"],"prefix":"10.1097","volume":"101","author":[{"given":"Linping","family":"Gu","sequence":"first","affiliation":[{"name":"Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiang","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7749-7313","authenticated-orcid":false,"given":"Hong","family":"Jian","sequence":"additional","affiliation":[{"name":"Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000336975","article-title":"Thyroid cancer: role of RET and beyond.","volume":"1","author":"Carlomagno","year":"2012","journal-title":"Eur Thyroid J"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.","volume":"30","author":"Wang","year":"2012","journal-title":"J Clin Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and translational implications of RET rearrangements in non-small cell lung cancer.","volume":"13","author":"Ferrara","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-2600(16)30322-8","article-title":"Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.","volume":"5","author":"Yoh","year":"2017","journal-title":"Lancet Respir Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2159-8290.CD-19-1116","article-title":"Advances in targeting RET-dependent cancers.","volume":"10","author":"Subbiah","year":"2020","journal-title":"Cancer Discov"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study.","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1158\/1078-0432.CCR-20-3208","article-title":"A performance comparison of commonly used assays to detect RET fusions.","volume":"27","author":"Yang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"101911","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors.","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-020-01427-4","article-title":"Pralsetinib: first approval.","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"15_suppl","key":"R10-20250504","doi-asserted-by":"crossref","first-page":"9515","DOI":"10.1200\/JCO.2020.38.15_suppl.9515","article-title":"Registrational dataset from the phase I\/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).","volume":"38","author":"Gainor","year":"2020","journal-title":"J Clin Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.7150\/thno.34070","article-title":"Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.","volume":"9","author":"Tong","year":"2019","journal-title":"Theranostics"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/1759-7714.13006","article-title":"Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling.","volume":"10","author":"Guo","year":"2019","journal-title":"Thoracic Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:10:38Z","timestamp":1746335438000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":12,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031480","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,11,25]]}}}